ERBB2 c.1273T>C ;(p.F425L)

Variant ID: 17-37871749-T-C

NM_004448.2(ERBB2):c.1273T>C;(p.F425L)

This variant was identified in 3 publications

View GRCh38 version.




Publications:


Targeting the PI3K and MAPK pathways to improve response to HER2-targeted therapies in HER2-positive gastric cancer.

Journal Of Translational Medicine
Mezynski, M Janusz MJ; Farrelly, Angela M AM; Cremona, Mattia M; Carr, Aoife A; Morgan, Clare C; Workman, Julie J; Armstrong, Paul P; McAuley, Jennifer J; Madden, Stephen S; Fay, Joanna J; Sheehan, Katherine M KM; Kay, Elaine W EW; Holohan, Ciara C; Elamin, Yasir Y; Rafee, Shereen S; Morris, Patrick G PG; Breathnach, Oscar O; Grogan, Liam L; Hennessy, Bryan T BT; Toomey, Sinead S
Publication Date: 2021-05-01

Variant appearance in text: ERBB2: F425L
PubMed Link: 33933113
Variant Present in the following documents:
  • Main text
View BVdb publication page



The HER2 S310F Mutant Can Form an Active Heterodimer with the EGFR, Which Can Be Inhibited by Cetuximab but Not by Trastuzumab as well as Pertuzumab.

Biomolecules
Shin, Jung Won JW; Kim, Soohyun S; Ha, Suji S; Choi, Byungsan B; Kim, Seongyeong S; Im, Seock-Ah SA; Yoon, Tae-Young TY; Chung, Junho J
Publication Date: 2019-10-19

Variant appearance in text: HER2: F425L
PubMed Link: 31635022
Variant Present in the following documents:
  • Main text
  • biomolecules-09-00629.pdf
View BVdb publication page



Effects of trastuzumab and afatinib on kinase activity in gastric cancer cell lines.

Molecular Oncology
Keller, Simone S; Zwingenberger, Gwen G; Ebert, Karolin K; Hasenauer, Jan J; Wasmuth, Jacqueline J; Maier, Dieter D; Haffner, Ivonne I; Schierle, Katrin K; Weirich, Gregor G; Luber, Birgit B
Publication Date: 2018-04

Variant appearance in text: ERBB2: F425L
PubMed Link: 29325228
Variant Present in the following documents:
  • MOL2-12-441-s001.pdf
View BVdb publication page